Abstract:Background: Dupilumab has been shown to be effective in clinical trials for moderate-to-severe uncontrolled asthma. However, the efficacy of dupilumab in the real world and the prediction of treatment response have not been well studied in patients with asthma. Objective: To investigate the efficacy of dupilumab and explore predictors of super-responders in a Chinese retrospective cohort. Methods: From January 2021 through December 2022, the patients with uncontrolled asthma who were treated with dupilumab for 4 months were included. Symptom control, type 2 inflammatory biomarkers, and lung function were collected at baseline and follow-up for efficacy assessment. Super-responders were defined as exacerbation-free, off maintenance of oral corticosteroids (mOCS), and with a score of the five-item Asthma Control Questionnaire (ACQ-5) of <0.5. The uni- and multivariable logistic regressions were used to construct predictive models for super-responders based on baseline features. Results: A total of 53 patients were included. After 4 months treatment, the median (interquartile range [IQR]) ACQ-5 score decreased from 1.8 (1.6‐2.4) to 0.4 (0.2‐0.8) (p < 0.001), the median (IQR) number of exacerbations, from 0.0 (0.0‐1.0) to 0.0 (0.0-0.0) (p = 0.005). The median (IQR) dose of mOCS (prednisone equivalent) decreased from 15.0 mg/day (8.8‐22.5 mg/day) to 2.5 mg/day (0.0‐10.0 mg/day) (p = 0.008) in nine patients who were receiving mOCS. All efficacy assessment parameters, including sputum eosinophil were significantly improved, while blood eosinophil count did not decline (530 cells/mm 3 [300‐815 cells/mm 3 ] versus 560 cells/mm 3 [220‐938 cells/mm 3 ], p = 0.710). After taking dupilumab, 25 of 53 patients (47.2%) achieved a super-response. The age of onset < 42 years (odds ratio [OR] 7.471 [95% confidence interval {CI}, 1.286‐43.394) and the baseline fractional exhaled nitric oxide (FeNO) of 25‐50 ppb (OR 35.038 [95% CI, 3.104‐395.553]) predicted super-responders, which showed a C-index of 0.822 (95% CI, 0.697‐0.947). Conclusion: Dupilumab significantly improved symptom control, type 2 inflammatory markers, and lung function in Chinese patients with uncontrolled asthma. Airway eosinophils, rather than blood eosinophils, can be a reliable indicator of therapeutic efficacy. The early-onset asthma as well as the medium-high level of baseline FeNO contributed to the prediction of super-responders.

Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China

Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

Efficacy of dupilumab in patient with hypereosinophilic syndrome and asthma non-responsive to anti-IL5 and anti-IL5r treatment.

Blood eosinophilia in patients with severe bronchial asthma and chronic polypous rhinosinusitis treated with dupilumab: A review

Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort

Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

Asthma loss of control after switch from anti-IL5/5R drugs to dupilumab in severe eosinophilic asthma: a case series.

Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Effectiveness of dupilumab on lung function in severe eosinophilic asthma

Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing

Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma

THE EFFECT OF DUPILUMAB ON LUNG FUNCTION BY ALLERGEN SENSITIZATION STATUS IN PEDIATRIC ASTHMA

The Efficacy and Safety of Dupilumab in Chinese Patients with Moderate-to-severe Atopic Dermatitis: a Randomized, Double-Blind, Placebo-Controlled Study.

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab